Navigation Links
Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
Date:7/31/2012

inflammation.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "planned," "believe," "forecast," "estimated," "expected," and "intend," among others. These forward-looking statements are based on Synergy's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Synergy's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.  While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the d
'/>"/>

SOURCE Synergy Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... FRANCISCO, Calif. , Aug. 3, 2015 /PRNewswire/ ... the treatment of cancer, today announced the promotion ... Debanjan Ray , who previously served ... management, has been promoted to senior vice president ... CytomX, Mr. Ray held positions as the vice ...
(Date:8/3/2015)... OSAKA, Japan and FLORHAM PARK, ... today announced that once-daily naldemedine met its primary and ... for the treatment of opioid-induced constipation (OIC) in adult ... oral, peripherally acting mu-opioid receptor antagonist (PAMORA). This is ... its primary and key secondary endpoints. Study ...
(Date:8/3/2015)... Inc. (PK:ECIA), a medical device company owning patented surgical ... invasive surgery, today announced financial results for its fiscal ... The Company posted quarterly net revenue of $2.454 ... or $(0.02) per share. These results compare to net ... $202 thousand, or $(0.02) per share, in the year-ago ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... , ST. LOUIS , Feb. 8 ... its first Stereotaxis Magnetic Navigation System in Taiwan at ... a Grand Opening event on January 26 that received ... been successfully performed using Stereotaxis at the hospital. , "All too ...
... Md. , Feb. 8 Novavax, Inc. (Nasdaq: ... to discontinue negotiations in its pursuit of the previously announced ... Novavax,s virus-like-particle (VLP)-based vaccines against influenza in the country of ... inability to agree on acceptable terms of the proposed collaboration ...
Cached Medicine Technology:Stereotaxis Installs First System in Taiwan 2Stereotaxis Installs First System in Taiwan 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 2Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 4
(Date:8/3/2015)... ... August 03, 2015 , ... ... ® and Navigant Center for Healthcare Research and Policy Analysis show widespread support ... of respondents said they agreed or strongly agreed that the controversial law passed ...
(Date:8/3/2015)... ... ... A July 9 article from USA Today has revealed a ... American Dental Association. According to a study by the American Dental Association, from 2000 ... single year to 2.2 million a year. Dentists and ADA officials all point to ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... global insurance brokerage firm, announced today that Joe Williams has joined its growing ... sales, and delivering HUB's differentiated service model to his clients. Mr. Williams will ...
(Date:8/3/2015)... ... ... The American Institute of Architects (AIA) and ... a wide range of initiatives ranging from code development and compliance to sustainability ... membership, consisting of practicing design professionals, code officials, and the building industry representatives, ...
(Date:8/2/2015)... ... August 03, 2015 , ... For many “would be” entrepreneurs, starting a new business can ... can’t afford to start a business.” Neither needs be a major obstacle. , The ... to start a business and be successful. The risks of starting a business can be ...
Breaking Medicine News(10 mins):Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5
... how much control a person has over their own health ... that when doctor and patient attitudes on the issue match ... Published online and in the May issue of the ... part of a growing body of evidence indicating that patient-physician ...
... have already adopted guidelines, group says , WEDNESDAY, April ... for how medical organizations should interact with private companies ... Societies (CMSS). , "Physicians and patients count on medical ... medicine," Dr. Allen Lichter, CEO of the American Society ...
... In rats, approach minimized dangerous bleeding around spinal cord ... rats is raising new hope for a treatment that might ... often follows such trauma. , Researchers found that by immediately ... gene, they could halt the dangerous bleeding that occurs at ...
... ago that the genes BRCA1 and BRCA2 confer high ... for cancer prediction and therapy, especially for familial cases. ... rechts der Isar of the Technische Universitaet Muenchen), in ... the U.S., can identify another gene that increases susceptibility ...
... Older whites with less education least likely to be screened, ... few middle-aged and older white Americans are being screened for ... finish high school or receive other common cancer screenings, a ... white men and women, aged 50 and older, who took ...
... ... Barrel Safety Syringe , ... Mission Viejo, CA (Vocus) April 21, 2010 -- SafeShot Technologies, LLC , ... Dr. Robert W. Beart, Emeritus Professor of Surgery at Keck School of Medicine, University ...
Cached Medicine News:Health News:Patient-physician compatibility increases odds of following doctor's orders 2Health News:Patient-physician compatibility increases odds of following doctor's orders 3Health News:Voluntary Ethics Code Set for Medical Organizations 2Health News:Gene-Targeted Therapy Might Help Prevent Paralysis 2Health News:Gene-Targeted Therapy Might Help Prevent Paralysis 3Health News:Researchers identify a new breast and ovarian cancer susceptibility gene 2Health News:Few Over 50 Get Skin Cancer Screenings 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 3
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Performa cemented stem....
Porous foundation 480 series....
Porous foundation 440 series....
Medicine Products: